TY - JOUR T1 - Petechial skin rash associated with CoronaVac vaccination: first cutaneous side effect report before phase 3 results JF - European Journal of Hospital Pharmacy JO - Eur J Hosp Pharm DO - 10.1136/ejhpharm-2021-002794 SP - ejhpharm-2021-002794 AU - Filiz Cebeci AU - İlkay Kartal Y1 - 2021/05/24 UR - http://ejhp.bmj.com/content/early/2021/05/23/ejhpharm-2021-002794.abstract N2 - Due to the newness of the virus, side effects of vaccines specific to SARS-CoV-2 are not yet known. CoronaVac, a purified inactivated SARS-CoV-2 vaccine developed by Sinovac Biotech (Beijing, China), has been shown to induce SARS-CoV-2-specific neutralising antibodies in mice, rats, non-human primates and in macaques.1 CoronaVac was shown to be well tolerated and did not cause dose-related safety concerns in phase 1 and 2 clinical studies involving healthy individuals aged 18–59 years2 and those aged 60 years and older.3 The most common symptom was injection site pain, and hypersensitivity reactions were the least reported side effects.2 We do not know the phase 3 efficacy and side effect results of CoronaVac, although vaccination has started. Turkey has decided on the CoronaVac within the vaccine market and is currently continuing the vaccination of elderly people following health workers. Here we share up-to-date data on an elderly person who developed post-vaccination side effects in the form of a petechial rash.An 82-year-old woman presented with weakness, burning in the legs and a rash. A diffuse petechial rash was observed on both lower extremities during dermatological examination (figure 1A,B). It was learned that … ER -